key: cord-0924989-sdwfgdz7 authors: Reichelt, Angela J.; Hirakata, Vânia N.; Genro, Vanessa K.; Oppermann, Maria Lúcia R. title: A snapshot of the prevalence of endocrine disorders in pregnancies complicated by coronavirus disease 2019: A narrative review with meta‐analysis date: 2021-05-29 journal: Int J Gynaecol Obstet DOI: 10.1002/ijgo.13714 sha: 5a60aab63c503e4605eb8a5bece799970f36d293 doc_id: 924989 cord_uid: sdwfgdz7 BACKGROUND: Some maternal characteristics indicate worse prognosis in pregnant women with coronavirus disease 2019 (COVID‐19). OBJECTIVE: To describe the prevalence of endocrine disorders in pregnancies involving COVID‐19, and its impact on maternal outcomes. SEARCH STRATEGY: Search terms were “pregnancy” and “COVID‐19”. SELECTION: PubMed, Embase, medRxiv, and Cochrane worksheet from February to July 2020 were searched. DATA COLLECTION AND ANALYSIS: Articles describing endocrine disorders in pregnancies with and without COVID‐19 involvement were considered. We performed meta‐analyses of prevalence using random‐effect models and estimated relative risk and 95% confidence intervals (CI) of maternal outcomes relative to presence of endocrine disorders. MAIN RESULTS: Articles included (n = 141) were divided into three data sets: individual (119 articles, 356 women), case series (17 articles, 1064 women), and national registries (7 articles, 10 178 women). Prevalence of obesity ranged from 16% to 46% and hyperglycemia in pregnancy (HIP) ranged from 8% to 12%. In data set 1, HIP and obesity were risk factors for severe disease in crude and age‐adjusted models, although not for intensive care unit admission. In data from two national registries, risk of dying was 5.62 (95% CI 0.30–105.95) in women with diabetes and 2.26 (95% CI 1.03–4.96) in those with obesity. CONCLUSION: Obesity and HIP were prevalent in pregnant women with severe COVID‐19. described outcomes of nine pregnancies in Chinese women; they were in the third trimester and the authors focused on the possible vertical transmission of COVID-19 during labor. Cases occurred from January 20, 2020 onward in Zhongnan Hospital of Wuhan University. 3 Since then, a myriad of articles have appeared in the literature, most of them as case reports or case series. After the spread of the disease to other continents, more consistent reports became available. 1 As described for non-pregnant adults, 4 some features seem to behave as risk factors for more severe forms of COVID-19 and worse pregnancy outcomes; among them, obesity, chronic hypertension, diabetes (pre-gestational or gestational diabetes), and smoking were described. 1 In this narrative review with meta-analysis, we investigate the prevalence of endocrine disorders in pregnant women positive for COVID-19 and the burden that these disorders impose on pregnancy outcomes. Our review was registered in PROSPERO on June 22, 2020, CRD42020192063. 5 The study was approved on August 18, 2020 by the ethics committee of Hospital de Clínicas de Porto Alegre (CAAE 35017020600005327), project 2020-0382. We performed a systematic search for articles describing the presence of endocrine disorders in pregnant women positive for COVID-19, irrespective of study design or primary outcome and severity of infection, at any gestational age and either outpatients or inpatients, pre-delivery or post-delivery. We searched PubMed, Embase, medRxiv, and the Cochrane excel sheet "Perinatal outcomes in COVID-19 infection" available from the Cochrane Gynaecology and Fertility site. 6 No restriction for language was applied, except for manuscripts written exclusively in Chinese that could not be electronically translated. Case series/case reports and cohort studies from the first published report (February 2020) until July 3, 2020 for PubMed and Embase and until July 15, 2020 for medRxiv and the Cochrane excel worksheet, were inserted in the database. A broad search strategy was used in PubMed, Embase, and medRxiv: (pregnancy) and , because of the paucity of studies at the time of the search (see Appendix S1). AJR, MLRO, and VKG screened article titles and abstracts. All articles listed in the Cochrane worksheet were eligible, after obtaining the permission of Dr Madelon van Wely. Studies were screened for relevance and eligibility. We extracted information on location of the study (country, city, and setting), study design, maternal age, ethnicity, gestational age (or trimester) at diagnosis, body mass index (BMI; calculated as weight in kilograms divided by the square of height in meters), categorization of BMI, diabetes (pre-gestational or gestational or other), thyroid disorders (hypothyroidism or hyperthyroidism), diagnostic tool for COVID-19, severity of disease, maternal and pregnancy outcomes, frequency of endocrine disorders in non-COVID-19 and COVID-19 cases, and frequency according to disease severity. COVID-19 was deemed positive if the reverse-transcriptase polymerase chain reaction test detected SARS-CoV-2 or if lung images by computed tomography were those typically found in the disease. 7 We did not include studies reporting women with serologic diagnostic tests, except for one woman. 8 If severity of disease was not described, we used the World Health Organization recommendation of a four-level classification: asymptomatic disease, mild disease, moderate (presence of pneumonia/hospital admission) disease, and severe/critical disease. 7 Endocrine disorders were extracted as reported by the authors: normal BMI, overweight, obesity, diabetes, pre-gestational diabetes (PGDM), gestational diabetes (GDM), hypothyroidism, hyperthyroidism, and any other. We considered BMI as normal when clearly reported, or if authors stated that women had no comorbidities, were deemed as fit or pregnancy was classified as uneventful. BMI was considered as pre-gestational if stated or when reported with other pre-pregnancy morbidities; and as calculated in pregnancy if authors reported so. Hyperglycemia in pregnancy (HIP) refers to any kind of diabetes in pregnancy. 9 The main outcome was prevalence of endocrine disorders. Intensive care unit (ICU) admission and death were the outcomes for risk estimation. AJR and VKG extracted data in an SPSS sheet. After extraction, AJR, VKG, and MLRO, in pairs, confirmed and corrected the data. Discordances were discussed with MLRO or VNH. Several authors were contacted to provide additional data on participants or to clarify information. Studies were evaluated by the Quality Assessment Tool for Case Series (https://www.nhlbi.nih.gov/healt h-topic s/study -quali ty-asses sment -tools; accessed February 17, 2021). The tool encompasses nine queries: study objective, case definition, consecutiveness, comparability, intervention, outcome definition, length of follow up, statistical methods, and results well described. Intervention did not apply here; consecutiveness and comparability did not apply to case reports. Therefore, the maximum score was 5 for individual reports and 8 for case series. Studies were ranked as good (score 4 to 5, individual reports; 6 to 8, case series), fair (score 3, individual reports; 4 to 5, case series) or poor (score 1 to 2, individual reports; 1 to 3, case series). During data extraction, we realized that some cases could be duplicated because authors focused on different disease aspects of the same pregnancy, reporting them in independent articles. Cases considered similar were further scrutinized for hospital of origin, dates of admission or delivery, maternal age, gestational age, and data on the neonate. Due to evidence of duplicated reports, we decided to perform analyses combining articles into three groups. Individual data could be extracted from 119 articles, some originally reported as case series (see Appendix S2, data set 1; Supplementary references 1-119); case series were reported in 17 articles (see Appendix S3, data set 2; Supplementary references 120-136); and seven articles provided data from five national registries, 10-14 a national COVID-19 reference hospital 15 and a national study group of obstetricians and gynecologists, 16 comprising the third data set. We calculated prevalence and 95% CI of each endocrine disorder. Meta-analysis of prevalence was performed using randomeffect models in data sets 2 and 3. Cochrane χ 2 and I 2 tests were used to evaluate heterogeneity among studies, and an α value of 0.10 was considered significant. Publication bias was assessed using a funnel plot of study's effect size against standard error. Funnel plot asymmetry was evaluated by Begg and Egger tests. Due to the small number of studies in each data set, trim and fill and sensitivity analyses were not performed. Relative risks and 95% CI were calculated for maternal outcomes using Poisson regression with robust estimation of variance. Evaluable outcomes were disease severity and admission to ICU in data set 1, and cure or death in data set 3. SPSS version 18 (IBM Corp., Armonk, NY, USA), R and WIN-PEPI programs were used to perform analyses. We wrote the article following the Preferred Reporting Items for Systematic Reviews and Meta-Analysis (PRISMA) statement. 17 References were updated to the most recent version. We identified 1227 titles/abstracts, of which 234 were eligible. After exclusions, many during the extraction process, 141 articles remained for final synthesis (PRISMA diagram, see Figure S1 ). In Figure 1 , we present number of cases described in 62 studies, after excluding probable duplicates (n = 10 717 women), grouped by continent of the original publication. No cases were reported in Oceania and only a few in Africa; reports from Asia totaled 512 cases, from Latin America, 293, and from Europe, 1380. The largest series was from the USA, a report from the Centers of Disease Control involving 8207 women 11 ; reports from North America contributed with more than 8500 cases. The analyses within each data set are described below. One hundred and nineteen articles provided individual information about 356 women with COVID-19. Individual cases were described in 70 papers (19.7%) and the other 286 (80.3%) were extracted from papers describing series of cases. More than half of reports were from university hospitals; 114 (32.0%) women were from China, 102 (28.7%) were from Europe; 86 (24.2%) from the USA and the others were from Latin America, Africa, and other Asian countries. Risk of having severe COVID-19 disease if a morbidity was present is exhibited in Table 2 . Obesity and HIP were risk factors in both crude and age-adjusted models. Obesity heightened the risk of severe disease in crude and adjusted models, but HIP was not significant when adjusted for obesity. Risk of admission to ICU was two times higher in women with obesity and in those with PGDM (Table 2) . Obesity was significant in the age-adjusted model, but not in a model adjusted by maternal age and hyperglycemia; after adjustments for maternal age and obesity, risk attributed to PGDM did not remain significant. Due to the low prevalence of other endocrine disorders, no risk analyses were performed. In this section, we included 17 articles. Eight papers were from the USA, two from each of China, Spain, and the UK, and one from each of India, Italy, and Sweden. Quality of studies was good (see Table S1 , Panel B, left side). and not specified in one (11.1%). Figure 1 shows prevalence of obesity in the nine series (n = 599); obesity was present in one-third of cases, with high heterogeneity among studies (prevalence 33%; 95% CI 23-45), I 2 84%, P < 0.01). Information on the presence of diabetes was provided in 16 articles: in two papers, there were no cases of diabetes; in the other 14, diabetes was described as pre-existing or GDM in 10 articles, and generically as diabetes in the other four. In one paper, cases of diabetes were under the umbrella of comorbidities. 18 Prevalence of hyperglycemia in pregnancy (14 articles, 1022 women) was 9% (95% CI 6-12). Gestational diabetes was described in seven papers (653 women) with a prevalence of 8% (95% CI 6-12). Pregestational diabetes was described in six studies (502 women) with a prevalence of 5% (95% CI 3-7); and diabetes was reported in five studies (280 women) with a prevalence of 7% (95% CI 3-15) ( Figure 1 ). Thyroid diseases were reported in 16 papers: there were nine cases of hypothyroidism and one case of hyperthyroidism described in four articles. [19] [20] [21] [22] Meta-analysis was not conducted. We could not group studies to calculate the risk of adverse pregnancy outcomes because of the low number of risk factors or outcomes. No other endocrine disorders were reported. Among the seven articles in this section, one was from Kuwait, three were from Europe (France, Italy, and the UK) and three were from the Americas (Brazil, Mexico, and the USA). All studies were of good quality (see Table S1 , Panel B, right side). The studies provided data on 10 178 pregnancies in women with Prevalence of endocrine disorders in data set 3 is shown in Figure 2b ; obesity and GDM were the most frequent disorders, with prevalence higher than 10%. Prevalence of individual endocrine conditions was: obesity 16% (95% CI 9-27, I 2 96%, P < 0.01); GDM 11% (95% CI 10-13, I 2 0%, P = 0.87); PGDM 2% (95% CI 2-3, I 2 0%, P = 0.22); diabetes 6% (95% CI 3-9), I 2 90%, P < 0.01; HIP 8% (95% CI 5-12, I 2 95%, P < 0.01); and hypothyroidism 2% (95% CI 1-5, Two papers, 10, 13 involving 596 women, could be compared because they used similar definitions: obesity (not classified as pre-gestational or in pregnancy) and diabetes (not specified) as risk factors, and cure or death as maternal outcomes (see Figure S2 ). Publication bias was not significant in either data set 2 or data set 3, except for HIP in data set 2, case series (P = 0.028). Funnel plot analyses are shown in the Figure S3 . In the three settings, obesity was the most prevalent endocrine disorder in pregnant women with COVID-19, with rates from 16% to 46%. Hyperglycemia in pregnancy ranged from 6% to 12%. The presence of these morbidities was associated with unfavorable maternal outcomes. Other endocrine disorders were rare. A state of inflammation is associated with obesity and diabetes. This is, probably, the hallmark aspect by which these disorders behave as risk factors for SARS-CoV-2 infection and, moreover, as predictors of severe forms of the disease with worse outcomes. Adipose tissue is vulnerable to hyperplasia and hypertrophy and these alterations, mediated by tissue hypoxia, provoke increased release of inflammatory elements. The misbalance between increased inflammatory cytokine release and diminished action of the antiinflammatory immune system results in chronic and diffuse inflammation. 23 Other mechanisms, such as an increased pro-thrombotic profile, can further contribute to the severity of COVID-19. 24 Conversely, pregnancy is a state of active and complex immune changes that lead to maternal tolerance for successful implantation of the trophoblast/blastocyst unit. 25 These alterations may potentially increase the susceptibility of pregnant women to SARS-CoV-2 infection. In a meta-analysis, prevalence of severe COVID-19 was 7% (95% CI 4-10) if universal screening of women arriving for delivery was performed, and 18% (95% CI 10-28) in symptomatic women. 1 TA B L E 2 Risk of adverse outcomes in pregnancies with endocrine disorders (articles with individual data) Conversely, data from large national registries may encompass incomplete information or use broader definitions of several parameters, such as for diabetes, without specifying if GDM or type 1/type 2 PGDM were present; case series may provide more accurate data on this. Finally, the possibility of duplicated cases precluded inclusion of several studies. We are convinced that these limitations are mostly explained by the rush to publish information about this new, dangerous, and multifaceted disease that rapidly spread worldwide, in such way that a pandemic had to be declared. In conclusion, among pregnant women with COVID-19, obesity was a prevalent risk factor, followed by hyperglycemia, similar to what is described outside pregnancy. Due to the scarce and sometimes confusing data available, more studies are deemed necessary to elucidate the role of endocrine disorders in the outcomes of pregnancies complicated by COVID-19. Alegre (the hospital fund for research). The funding source (FIPE-HCPA) had no role in study conception, conduction or writing. The authors have no conflicts of interest. AJR was responsible for conception of the study; all authors contributed to planning and carrying out the study. All authors were Clinical manifestations, risk factors, and maternal and perinatal outcomes of coronavirus disease 2019 in pregnancy: living systematic review and meta-analysis COVID-19 & Pregnancy Cases: Updated Primary Scientific Reports with Professor Jim Thornton Clinical characteristics and intrauterine vertical transmission potential of COVID-19 infection in nine pregnant women: a retrospective review of medical records Coronavirus disease (COVID-19): a systematic review and meta-analysis to evaluate the impact of various comorbidities on serious events A snapshot of the prevalence of endocrine disorders in pregnancies complicated by COVID-19 (a narrative review) Excel sheet Perinatal outcomes in COVID-19 infection Clinical Management of COVID-19. Interim Guidance Considerations on COVID-19 pregnancy: a cases series during outbreak in Bergamo Province, North Italy World Health Organization. Diagnostic criteria and classification of hyperglycaemia first detected in pregnancy: a World Health Organization guideline Characteristics of women of reproductive age with laboratory-confirmed SARS-CoV-2 infection by pregnancy status-United States Characteristics and outcomes of pregnant women admitted to hospital with confirmed SARS-CoV-2 infection in UK: National Population Based Cohort study Maternal mortality from COVID-19 in Mexico Coronavirus and birth in Italy: results of a national population-based cohort study Maternal and perinatal characteristics and outcomes of pregnancies complicated with COVID-19 in Kuwait A snapshot of the Covid-19 pandemic among pregnant women in France Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement Universal SARS-Cov-2 screening in women admitted for delivery in a large managed care organization Maternal COVID-19 infection, clinical characteristics, pregnancy, and neonatal outcome: a prospective cohort study Clinical characteristics of 46 pregnant women with a severe acute respiratory syndrome coronavirus 2 infection in Washington State Impact of the coronavirus infection in pregnancy: a preliminary study of 141 patients Clinical manifestation and neonatal outcomes of pregnant patients with coronavirus disease 2019 pneumonia in Wuhan Obesity and COVID-19: molecular mechanisms linking both pandemics COVID-19 in people with diabetes: understanding the reasons for worse outcomes The unique immunological and microbial aspects of pregnancy Features of 20 133 UK patients in hospital with covid-19 using the ISARIC WHO clinical characterisation protocol: prospective observational cohort study Predicting mortality due to SARS-CoV-2: a mechanistic score relating obesity and diabetes to COVID-19 outcomes in Mexico Assessing risk factors for severe forms of COVID-19 in a pregnant population: a clinical series from Lombardy, Italy A snapshot of the prevalence of endocrine disorders in pregnancies complicated by coronavirus disease 2019: A narrative review with meta-analysis responsible for data analyses and writing of the manuscript and all endorsed the final version of the manuscript. https://orcid.org/0000-0002-9393-3445